Yeh I understand your point, and thoughts from bring burnt before.
The MST financial report gave a good view of future expectations around AA approvals for novel treatment for unmet needs, by memory 70%+ were approved in this category for AA, compared to something like 40%- for treatable medications (good read if you have time).
I think by crunching the data and aiming for AA primarily will significantly raise the stakes and profile of Alterity, particularly when wanting a substantial partner.
As for the number of recruitments, I think the financail position at the time, and given the rarity of the disease, it would have taken alot more time to round up more. But as the AI stated, with AA acceptance, these targets must be continually met and reported.
With the remaining 8 that you say are unaccounted for, that would be a good Q. to flick through to Alterity.
ATH Price at posting:
1.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)